India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#182- Valuation
- ₹33,320 Cr
Revenue · FY 2025
₹5,363.3 Cr
▲ 5% YoY
Net profit · FY 2025
₹1,700.65 Cr
Net margin 31.7%
EBITDA · FY 2025
₹2,361.68 Cr
EBITDA margin 44%
Authorised capital
₹99 Lakh
Registered with MCA
Paid-up capital
₹98.97 Lakh
Issued & subscribed
Satisfied charges
₹7.61 Cr
No open charges
Company age
55 yrs
Est. 1971
Employees · EPFO
9,848
Provident fund records
About Aristo Pharmaceuticals Private Limited
Data last updated:
Aristo Pharmaceuticals Private Limited is a private limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 08 November 1971 and has been in existence for over 55 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24239MH1971PTC015425. Its GSTIN is 27AAACA4495N1Z8 (Maharashtra). The company holds 17 GST registrations, of which 15 are active.
The company has an authorised share capital of ₹99 Lakh and a paid-up capital of ₹98.97 Lakh. It was formerly known as Aristo Pharmaceuticals Limited. It is led by directors including Umesh Sharma (Managing Director) and Randhir Kumar Bachan (Whole-Time Director).
Its last annual general meeting (AGM) was held on 05 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Mumbai, Maharashtra.
As per the financials filed for FY 2025, the company reported a revenue of ₹5,363.3 Cr, a growth of 5% compared to the previous year. For the same year it recorded a net profit of ₹1,700.65 Cr (net margin 31.7%) and EBITDA of ₹2,361.68 Cr (EBITDA margin 44%). Revenue has grown at a compounded annual rate (CAGR) of 8% over three years and 11% over five years.
The company has about 9,848 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Aristo Pharmaceuticals. As per MCA filings, the company has satisfied charges of ₹7.61 Cr on record. Court records list 285 cases involving the company, including 169 filed by the company and 116 filed against it; 75 cases are pending. The company has 10 deals on record (9 secondary share transfers, 1 funding round), with disclosed funding of ₹74 Lakh; the latest was in December 2020. Its 10 peer companies in the Pharma industry (Formulations, Pharmaceuticals) are compared by revenue, 5 larger and 5 smaller; the largest is Jubilant Pharmova Limited with revenue of ₹7,291.3 Cr. The company has 8 MSME Form 1 returns on record between 2019 and 2022, listing 2,203 overdue payments to 54 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website aristopharma.org.
Company Details of Aristo Pharmaceuticals Private Limited
CIN U24239MH1971PTC015425
Registration Number 015425
Incorporation Date 08 November 1971
ROC Mumbai
Listing Status Unlisted
Company Status Active
Date of Last AGM 05 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Umesh Sharma Managing Director Randhir Kumar Bachan Whole-Time Director Virendra Sharma Director Recognitions & Rankings of Aristo Pharmaceuticals
Contact Details
- EmailLocked
- TelephoneLocked
- Website
- Social Media
- Registered AddressGala No.2 Ground Floor 23 – A Shah Industrial Estate Off Veera Desai Road Andheri(West) Mum, Bai 400053, Mumbai, Maharashtra, India – 400053
- IndustryPharma, Drug Formulation & Development
Comprehensive company report
Aristo Pharmaceuticals Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Associated Brands with Aristo Pharmaceuticals Private Limited
Aristo Pharmaceuticals operates one associated brand: Aristo Pharmaceuticals. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Pharmaceutical manufacturing and innovation in various therapeutic segments are conducted by Aristo Pharma. | aristopharma.co.in |
Business Activity of Aristo Pharmaceuticals Private Limited
The main business activity of Aristo Pharmaceuticals is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Premium access
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Aristo Pharmaceuticals Private Limited FY 2025 filings available
Aristo Pharmaceuticals Private Limited reported revenue of ₹5,363.3 Cr (up 5% YoY) for FY 2025.
Revenue · FY 2025
₹5,363.3 Cr ▲ 5%
Net profit · FY 2025
₹1,700.65 Cr margin 31.7%
EBITDA · FY 2025
₹2,361.68 Cr margin 44%
Compounded Annual Growth Rate (CAGR) of Aristo Pharmaceuticals Private Limited
Revenue CAGR growth
1 year
▲ 5%
3 years · compounded
▲ 8%
5 years · compounded
▲ 11%
EBITDA CAGR growth
1 year
▲ 18%
3 years · compounded
▲ 13%
5 years · compounded
▲ 18%
Revenue has grown at a compounded annual rate (CAGR) of 11% over five years, including 5% growth in the latest year. EBITDA rose 18% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Aristo Pharmaceuticals Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹2,361.68 Cr | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹1,700.65 Cr | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Aristo Pharmaceuticals Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 44% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 31.7% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Aristo Pharmaceuticals are in the company report.
Premium access
Financial statements from 2015
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Board of Directors of Aristo Pharmaceuticals Private Limited
Aristo Pharmaceuticals has 3 current directors and 4 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Randhir Kumar Bachan Also directs: Mapra Laboratories Pvt Ltd | Whole-Time Director | 01 Sep 2005 | 21 Years 1 Months | Current |
| Virendra Sharma Also directs: Aristo Laboratories Private Limited, Nobel Enkem Private Limited | Director | 03 Oct 2006 | 20 Years 0 Months | Current |
| Umesh Sharma | Managing Director | 12 Feb 1979 | 47 Years 8 Months | Current |
Peer Comparison of Aristo Pharmaceuticals Private Limited
Aristo Pharmaceuticals Private Limited is compared with the companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Jubilant Pharmova Limited Listed | ₹7,291.3 Cr (FY 2025) | •••• | •••• | 8.0% | •••• | Uttar Pradesh, India |
| MSN Laboratories Private Limited | ₹6,761.18 Cr (FY 2024) | •••• | •••• | 27.0% | •••• | Hyderabad, Telangana, India |
| Alembic Pharmaceuticals Limited Listed | ₹6,714.63 Cr (FY 2025) | •••• | •••• | 7.0% | •••• | Vadodara, Gujarat, India |
| Abbott India Limited Listed | ₹6,684.73 Cr (FY 2025) | •••• | •••• | 10.0% | •••• | Mumbai, Maharashtra, India |
| Micro Labs Limited | ₹6,499.64 Cr (FY 2025) | •••• | •••• | -2.0% | •••• | Bengaluru, Karnataka, India |
| Aristo Pharmaceuticals Private Limited this company | ₹5,363.3 Cr (FY 2025) | •••• | •••• | 5.0% | •••• | Mumbai, Maharashtra, India |
| Usv Private Limited | ₹5,202.13 Cr (FY 2025) | •••• | •••• | 7.0% | •••• | Mumbai, Maharashtra, India |
| Eugia Pharma Specialities Limited | ₹4,828.71 Cr (FY 2025) | •••• | •••• | 12.0% | •••• | Hyderabad, Telangana, India |
| Natco Pharma Limited Listed | ₹4,784 Cr (FY 2025) | •••• | •••• | 16.0% | •••• | Hyderabad, Telangana, India |
| Ajanta Pharma Limited Listed | ₹4,742.6 Cr (FY 2025) | •••• | •••• | 10.0% | •••• | Mumbai, Maharashtra, India |
| Strides Pharma Science Limited Listed | ₹4,624.06 Cr (FY 2025) | •••• | •••• | 18.0% | •••• | Thane, Maharashtra, India |
Peers are the five companies nearest above and the five nearest below Aristo Pharmaceuticals by revenue in the Pharma industry (Formulations, Pharmaceuticals), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Aristo Pharmaceuticals Private Limited
Aristo Pharmaceuticals Private Limited is audited by R.S. PRABHU & ASSOCIATES for the financial year 2024.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| R.S. PRABHU & ASSOCIATES | Locked | Locked | Locked |
Premium access
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Ownership and Shareholding of Aristo Pharmaceuticals Private Limited
Premium access
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Aristo Pharmaceuticals Private Limited
Open charges
None
Satisfied charges
₹7.61 Cr
Breakdown by lending institutions
Latest charge details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 04 Mar 1993 | Srate Bank of India | ₹1 Cr | Satisfied |
| 08 Aug 1988 | State Bank of India | ₹5.05 Cr | Satisfied |
| 11 Dec 1980 | Bank of India | ₹40 Lakh | Satisfied |
| 14 Nov 1980 | Bank of India | ₹40 Lakh | Satisfied |
| 10 Mar 1979 | Bank of India | ₹53 Lakh | Satisfied |
Total charge records: 8 View all charges
Deals & Funding of Aristo Pharmaceuticals Private Limited
Aristo Pharmaceuticals Private Limited has 10 deals on record (9 secondary share transfers, 1 funding round), with disclosed funding of ₹74 Lakh; the latest was in December 2020.
Total deals
10
Secondary share transfers
9
Funding round
1
Disclosed funding
₹74 Lakh
Deals on record (5 of 10)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Dec 2020 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Aug 2018 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Dec 2017 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Jun 2017 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Mar 2016 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: 2 individuals |
Premium access
Full deal history
All 10 deals with amounts, valuations, instruments and every party are in the company report.
- Every funding round and share transfer
- Amounts and valuations
- Investors, buyers and sellers
- Instruments and deal dates
Verified entity values are shown only after access is granted.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal Cases of Aristo Pharmaceuticals Private Limited
Aristo Pharmaceuticals Private Limited has 285 court cases on record: 169 filed by Aristo Pharmaceuticals, 116 filed against it. 75 cases are pending and 210 are disposed.
Total cases
285
Filed by the company
169
Filed against the company
116
Pending
75
Disposed
210
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 175 | 54 | 57 |
| District courts | 96 | 49 | 16 |
| Supreme Court | 12 | 11 | 0 |
| NCLAT | 2 | 2 | 2 |
Cases on record (5 of 285)
| Court | Type of case | Party | Status |
|---|---|---|---|
| Bombay High Court | Court case (CRR) | Filed by the company against Geo Asa Life Sciences Private Limited | Pending |
| Bombay High Court | Court case (LPETN) | Filed by the company against Ultra Drugs Private Limited and 1 other | Pending |
| Bombay High Court | Court case (LPETN) | Filed by the company against Geo Asa Life Sciences Private Limited and 1 other | Pending |
| Bombay High Court | Court case (LPETN) | Filed by the company against Lividus Pharmaceuticals Private Limited and 2 others | Pending |
| Bombay High Court | Court case (CRR) | Filed by the company against Ultra Drugs Private Limited and Anr. | Pending |
Premium access
Full case history
All 285 cases with case numbers, court, year-wise trend, opposite parties and decision dates are in the company report.
- Every case with its case number
- Year-wise trend
- Opposite parties
- Decision dates and orders
Verified entity values are shown only after access is granted.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME Payment Delays by Aristo Pharmaceuticals Private Limited
Aristo Pharmaceuticals Private Limited has 8 MSME Form 1 returns on record between 2019 and 2022, listing 2,203 overdue payments to 54 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 54)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Mak Polyplast Private Limited | •••• | •••• | •••• |
| A.R.Pharma Packaging Private Limited | •••• | •••• | •••• |
| Adit Pharma Private Limited | •••• | •••• | •••• |
| Himalayan Capscon Industries | •••• | •••• | •••• |
| KC Overseas Private Limited | •••• | •••• | •••• |
Premium access
Full MSME payment history
Every supplier, amount and due date from all 8 MSME Form 1 returns is in the company report.
- Every reported supplier due
- Amounts and due dates
- Reasons given in each return
- Period-by-period history
Verified entity values are shown only after access is granted.
Individuals and sole proprietors among the suppliers are not named. Amounts, due dates and filing dates are in the company report.
Employees and EPFO Compliance at Aristo Pharmaceuticals Private Limited
Aristo Pharmaceuticals Private Limited has a workforce of 9,848 employees as of Feb 17, 2025.
Employee count
9,848
Active EPFO establishments
1
Employee growth
8.75%
Premium access
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Aristo Pharmaceuticals Private Limited
Aristo Pharmaceuticals Private Limited has 7 board changes on record since 1979: 3 appointments and 4 cessations. The latest: Raj Nandan Sharma ceased to be Director on 21 Sep 2017.
AGM
Aristo Pharmaceuticals Private Limited last Annual general meeting of members was held on 05 Sep 2025 as per latest MCA records.
Filing
Aristo Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai.
Charges
A charge registered on 11 Dec 1980 via Charge ID 90223705 with Bank Of India was fully satisfied on 06 Dec 2023.
Charges
A charge registered on 14 Nov 1980 via Charge ID 90223702 with Bank Of India was fully satisfied on 06 Dec 2023.
Charges
A charge registered on 10 Mar 1979 via Charge ID 90223681 with Bank Of India was fully satisfied on 06 Dec 2023.
Charges
A charge registered on 25 Feb 1974 via Charge ID 90223630 with Bank Of India was fully satisfied on 06 Dec 2023.
Charges
A charge registered on 29 Nov 1972 via Charge ID 90223621 with Bank Of India was fully satisfied on 06 Dec 2023.
Charges
A charge registered on 08 Aug 1988 via Charge ID 90220092 with State Bank Of India was fully satisfied on 14 Aug 2023.
Charges
A charge registered on 27 Feb 1974 via Charge ID 90223631 with State Industrial & Investment Corporation was fully satisfied on 17 Jul 2023.
Ceased
Raj Nandan Sharma ceased to be Director.
Charges
A charge registered on 04 Mar 1993 via Charge ID 90224399 with Srate Bank Of India was fully satisfied on 23 Dec 2015.
Ceased
Ranjit Sharma ceased to be Director.
15 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Aristo Pharmaceuticals Private Limited
Premium access
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Aristo Pharmaceuticals Private Limited
Premium access
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Aristo Pharmaceuticals Private Limited
Aristo Pharmaceuticals has 17 GST registrations: 15 active and 2 cancelled or inactive. The first 4 active GSTINs are listed below.
Total GSTINs
17
Active
15
Cancelled / inactive
2
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAACA4495N1Z8 | Maharashtra | Active | 01 Jul 2017 |
| 02AAACA4495N1ZK | Himachal Pradesh | Active | 01 Jul 2017 |
| 04AAACA4495N1ZG | Chandigarh | Active | 01 Jul 2017 |
| 06AAACA4495N1ZC | Haryana | Active | 01 Jul 2017 |
Premium access
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Aristo Pharmaceuticals Private Limited
Premium access
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aristo Pharmaceuticals Private Limited
Aristo Pharmaceuticals is an active private limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 08 November 1971 (55+ years old) and is registered under CIN U24239MH1971PTC015425.
Aristo Pharmaceuticals reported revenue of ₹5,363.3 Cr for FY 2025 (up 5% YoY).
Aristo Pharmaceuticals has 3 current directors:
- Umesh Sharma - Managing Director
- Randhir Kumar Bachan - Whole-Time Director
- Virendra Sharma - Director
Aristo Pharmaceuticals reported a net profit of ₹1,700.65 Cr (net margin 31.7%) and EBITDA of ₹2,361.68 Cr (EBITDA margin 44%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Aristo Pharmaceuticals is 8% over three years and 11% over five years. In the latest year (FY 2025) revenue rose 5%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Aristo Pharmaceuticals is 27AAACA4495N1Z8, registered in Maharashtra. The company has 17 GST registrations in all, of which 15 are active and 2 are cancelled or inactive. Other active GSTINs include 02AAACA4495N1ZK (Himachal Pradesh), 04AAACA4495N1ZG (Chandigarh), 06AAACA4495N1ZC (Haryana).
The CIN (Corporate Identification Number) of Aristo Pharmaceuticals is U24239MH1971PTC015425. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Aristo Pharmaceuticals has 285 court cases on record: 169 filed by the company and 116 filed against it. 75 are pending. Most are in the high courts.
Aristo Pharmaceuticals was incorporated on 08 November 1971, making it 55+ years old. It is registered with the Registrar of Companies, Mumbai.
Aristo Pharmaceuticals has 10 deals on record (9 secondary share transfers, 1 funding round), with disclosed funding of ₹74 Lakh; the latest was in December 2020.
The peers of Aristo Pharmaceuticals by revenue are Jubilant Pharmova Limited, MSN Laboratories Private Limited, Alembic Pharmaceuticals Limited, Abbott India Limited, Micro Labs Limited and 5 more, all in the Pharma industry (Formulations, Pharmaceuticals).
Raj Nandan Sharma ceased to be Director on 21 Sep 2017. Ranjit Sharma ceased to be Director on 23 Jun 2011. Devinder Rai ceased to be Director on 22 May 2008. Aristo Pharmaceuticals has 7 board changes on record in total.